cropper
National Cannabis Newswire
  • Home
  • Categories
    • news
    • trends
    • insights
    • industry
    • legalization
    • health
    • culture
    • advocacy
    • Brands
    • New Mexico Dispensaries
    • Arizona Dispensaries
2 Minutes Read

Melt-to-Make Patented Gummy Base Technology Supports Scalable Cannabis Edibles Manufacturing 

FOR IMMEDIATE RELEASE

Cannabis / Nutraceuticals / Manufacturing / Patent / Gummies / Growth / Scaling

“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president at Melt-to-Make.

NORTHAMPTON, Mass. — February 20, 2026 — As the global cannabis edibles market continues to expand, manufacturers are facing growing pressure to deliver compliant, consistent, and scalable products. According to Fortune Business Insights, the cannabis edibles market is projected to exceed $55 billion by 2034, reflecting sustained double-digit compound annual growth.

The expanding market is increasing demand for manufacturing systems that reduce formulation variability while improving production efficiency. In response, many producers are adopting standardized formulation platforms to support reliable output across product lines, facilities, and geographic markets.

Melt-to-Make has introduced a patented gelatin and pectin gummy base technology designed to address persistent bottlenecks in large-batch edible production. The company’s shelf-stable semi-finished gummy base can be heated and infused with active ingredients before molding, helping manufacturers simplify workflows while improving repeatability.

By standardizing the gummy base, the Melt-to-Make system reduces common manufacturing challenges associated with traditional confectionery production, including inconsistent texture, lengthy research and development cycles, and batch failures during scale-up.

“Our focus has been on removing unnecessary complexity from edible manufacturing,” said Sarah McLaughlin, MS, RD, co-founder and vice president of product development and research at Melt-to-Make. “When the formulation system itself is consistent and repeatable, manufacturers can concentrate on dosing precision and operational efficiency rather than troubleshooting structure and texture.”

Traditional gummy production often requires specialized confectionery equipment and advanced formulation expertise, particularly when working with pectin in vegan and heat-stable applications. Melt-to-Make’s semi-finished gummy base is designed to integrate into existing production workflows, giving manufacturers a more standardized substrate for predictable results.

As regulated cannabis markets in the United States and Europe continue implementing stricter quality control and labeling standards, consistency in edible production is becoming increasingly important for both regulatory compliance and long-term brand reliability.

Standardized ingredient systems are emerging as a practical solution for achieving repeatable performance in expanding markets. Melt-to-Make currently serves clients in more than 15 countries and provides technical documentation, formulation tools, and production support for manufacturers implementing the technology.

To learn more, visit www.melt-to-make.com.

About Melt-to-Make™

Founded in 2018 in Northampton, Massachusetts, by Sarah McLaughlin, Jake Goodyear, and Tim Van Epps, Melt-to-Make™ specializes in innovative gummy base systems designed to simplify large-batch gummy manufacturing. By offering professionally formulated gelatin and pectin bases that are approximately 90% complete, the company helps manufacturers produce gummies faster, more efficiently, and with greater consistency.

Melt-to-Make™ is committed to using all-natural ingredients and colors while supporting a wide range of consumer preferences, including vegan, gluten-free, and non-GMO options. The company serves more than 1,000 B2B customers across the United States and in 15 countries, offering comprehensive support that includes equipment lists, training videos, custom formulations, and on-site technical assistance.

For more information, visit www.melt-to-make.com or call 1-800-241-0341.

Media Contact

Proven Media
Kim Prince
Phone: 480-221-7995
Email: kim@provenmedia.com

news culture Brands

66 Views

0 Comments

Write A Comment

*
*
Please complete the captcha to submit your comment.
Related Posts All Posts

Cannabis Industry Firms Face Legal Scrutiny Over New Jersey's Union Licensing Requirements

Update Major MSOs Clash with New Jersey's Labor-Friendly Licensing In a notable turn of events for the cannabis industry, a second major multi-state operator (MSO) has filed a lawsuit against New Jersey, challenging the state's new labor-friendly licensing requirements that demand companies to hire union workers or demonstrate plans to engage with labor organizations. This legal battle raises crucial questions about the implications for the emerging cannabis market in New Jersey and may reshape the landscape for operators entering the industry. The Background of New Jersey's Licensing Requirements New Jersey's cannabis marketplace has undergone significant transformation since legalization in 2020, with an eye toward social equity and labor rights. The state's Comprehensive Cannabis Regulation and Equity Act mandates that companies making applications for licenses must outline their approach to labor relations. This requirement is intended to create a more equitable labor environment but has prompted backlash from major players in the cannabis market. What This Lawsuit Means for the Cannabis Industry The lawsuit could have ripple effects beyond New Jersey, drawing national attention to other states considering similar labor-centric regulations for their cannabis industries. Advocates argue that union jobs can secure higher wages and better working conditions. Meanwhile, opponents claim that such regulations stifle business operations and limit opportunities for growth. Potential Outcomes and Future Predictions If the case progresses in favor of the MSOs, New Jersey might need to revisit its regulations, potentially impacting how other states approach cannabis licensing. A ruling against the MSOs could reinforce or even expand labor protections nationwide, influencing practices across the burgeoning cannabis sector. Looking ahead, cannabis business owners nationwide are paying close attention to New Jersey as a potential test case for labor relationships in the industry. Cannabis and Labor: An Emotional Connection As the cannabis industry matures, the conflict between labor rights and business interests intensifies. Workers in the cannabis sector often share personal stories that highlight their struggles for better working conditions and fair wages, sparking emotional connections with customers and advocates alike. Understanding these narratives is essential for those exploring what is going on with cannabis. Take Action: Stay Informed As this legal saga unfolds, it’s critical for stakeholders in the cannabis industry to stay informed about the implications of labor-friendly requirements. Following updates and understanding the shifting dynamics can directly impact decisions made at all levels within the industry.

What is Going On With Cannabis? Canadian LPs Expand in Europe!

Update Canadian Cannabis LPs Make Waves in Europe As the global cannabis market continues to evolve, Canadian Licensed Producers (LPs) are keenly eyeing opportunities across the Atlantic. With Europe emerging as a potential hotspot for cannabis business and development, the involvement of Canadian players may dramatically shape the industry's landscape. Understanding Europe's Cannabis Market Europe's cannabis market is gradually expanding, fueled by a growing interest in medical and recreational cannabis use. Countries like Germany, which has a large population and a robust healthcare system, are paving the way for licensed medical use. With legalization efforts steadily advancing, many Canadian LPs are seeking to establish their presence early. Strategic Partnerships and Investments In pursuit of market share, Canadian LPs are forming alliances with local European businesses that have an established understanding of the regulatory landscape. These partnerships position them advantageously as they navigate the complexities of compliance and distribution in different markets. Why Canadian LPs? The Benefits Explained Marked by experience and a proven track record in regulated markets, Canadian LPs bring valuable expertise to Europe. Their dedication to quality, consistency, and safety aligns well with the stringent standards set forth by European regulators. For cannabis industry watchers, the focus on practices that prioritize patient needs and corporate responsibility will be crucial. Future Trends: What’s Next for the Cannabis Industry? As the European market continues to mature, Canadian LPs are poised to play significant roles in this evolution. There’s a palpable excitement surrounding new product innovation, with applications ranging from medicinal treatments to wellness products gaining traction. The anticipated expansion indicates a dynamic future for the global cannabis industry, contextualizing the importance of following these developments closely. Concluding Thoughts: Stay Informed With the cannabis industry rapidly changing, understanding the intricacies of this market is becoming increasingly important. For bloggers and industry enthusiasts, keeping tabs on how Canadian LPs are expanding their presence in Europe will provide valuable insights into global trends and opportunities.

How Aurora's Acquisition of a UK Pharmacy Shapes Patient Access

Update Aurora's Bold Move into the UK Cannabis Market In a decisive strategic shift, Aurora Cannabis (ACB) has made headlines by acquiring a UK pharmacy and import license for £2.1 million, a move designed to enhance its accessibility to patients in this burgeoning market. This acquisition, which includes Birmingham-based Internod Pharma and HAP Pharma, marks an important milestone for the company as it seeks to penetrate what it identifies as a significant growth area. Strengthening Patient Connections As the company faces unwelcome attention from one of the world’s largest cannabis corporations eyeing a takeover, the urgency for Aurora to establish a robust foothold in the UK has never been greater. Senior Vice President Andreas Dotterweich underscored the rationale behind this acquisition, emphasizing Aurora’s commitment to bringing medications closer to patients. He stated, “At the end of the day, it’s patient demand that drives us; owning a direct route to market gives us significant control over importation, distribution, and pharmacy capabilities.” This patient-centric approach is expected to streamline services and respond promptly to the needs of consumers. The Significance of the Acquisition The essence of Internod Pharma lies in its Wholesale Dealer’s Authorisation, which grants Aurora the legal right to import and distribute medical cannabis products directly within the UK. This regulatory license, signed by the UK Medicines and Healthcare products Regulatory Agency (MHRA), eliminates the need to engage third-party wholesalers, optimizing the supply chain. In contrast, HAP Pharma, while holding pharmacy credentials, has remained dormant since its inception in 2020, suggesting an opportunity for Aurora to revitalize its operations and launch effective patient services. Aura of Competition and Market Presence As Aurora fortifies its standing, analysts are already questioning its previous pace of expansion in the UK. During a recent earnings call, CEO Miguel Martin defended the company’s focus on genetics and product development over immediate market saturation with clinics and pharmacies, a domain where rivals have been more aggressive. The contrasting strategies between Aurora and its competitors illustrate the dynamic nature of the cannabis market, where speed often translates to market share. Next Steps for Aurora The question now surrounding Aurora is how quickly it can implement these acquisitions into a functional operation that resonates with both patients and healthcare professionals. With competition intensifying, Aurora must balance its foundational work in genetics and manufacturing with the pressing need for patient access and engagement. Creating meaningful relationships within the healthcare community will be pivotal as the company steps into the fray. Final Thoughts: Navigating the Future of Cannabis The UK cannabis market is evolving, and as industry leaders like Aurora invest strategically, their role will be watched closely by both competitors and potential patients. This acquisition not only strengthens Aurora’s operations but also sets a precedent for how companies can navigate the complex regulatory landscape while prioritizing patient needs. As cannabis gains visibility and acceptance, Aurora's endeavors may well reflect broader trends within the industry. For professionals in the cannabis community, keeping an eye on Aurora's progress will be crucial. What strategies might they employ next? Will this acquisition indeed translate to more direct patient connections? The answers lie in the near future as Aurora transitions from bold aspirations to operational execution.

National Cannabis Newswire
National Cannabis Newswire keeps you informed, empowered, and connected to the Cannabis community.

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6

480.878.1919

AVAILABLE FROM 8AM - 5PM PST

Contact

11504 W Piccadilly Rd,
Avondale, AZ 85392,

ABOUT US

Your source for breaking cannabis industry news, expert insights, and nationwide updates—National Cannabis Newswire keeps you informed, empowered, and connected.

© 2026 CompanyName All Rights Reserved. Address . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*